P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Overall Survival in Spine Myeloma Metastases: Difficulties in Predicting with Prognostic Scores.
Aymeric Amelot,Joseph Cristini,Céline Salaud,Alexis Moles,Olivier Hamel,Philippe Moreau,Eric Bord,Kevin Buffenoir +7 more
TL;DR: Spine surgical prognosis scores are not accurate and are not able to predict the survival of patients with spine myeloma metastases, and spine surgeons have to be guided not by the initial ISS stage but rather by spinal instability and neurological status.
Journal ArticleDOI
"Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment?".
TL;DR: It is argued that it is reasonable to include upfront ASCT in ypothesis-generating clinical trials designed with the intent of eveloping a cure for myeloma, but the hope provided by improveent in surrogate endpoints or the anticipated results of such trials is unclear.
Journal ArticleDOI
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis
Marcelo Capra,Thomas G. Martin,Philippe Moreau,Ross I. Baker,Ludek Pour,Chang-Ki Min,Xavier Leleu,Mohamad Mohty,Marta Segura,Mehmet Turgut,Richard Leblanc,Marie-Laure Risse,Laure Malinge,Sandrine Schwab,Meletios A. Dimopoulos +14 more
TL;DR: IKEMA was a randomized, open-label, multicenter, Phase 3 study that demonstrated the benefit of adding Isa to carfilzomib (K) plus d vs Kd in pts with relapsed MM, and was classified as durable if lasting ≥60 days.
Journal ArticleDOI
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
Jesús F. San-Miguel,Vania Hungria,Sung-Soo Yoon,Meral Beksac,Meletios A. Dimopoulos,Ashraf Elghandour,Wiesław Wiktor Jędrzejczak,Andreas Guenther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Robert L. Schlossman,Jian Hou,Philippe Moreau,Sagar Lonial,Jae Hoon Lee,Hermann Einsele,Hans Salwender,Monika Sopala,Suman Redhu,Sofia Paul,Claudia Corrado,Paul G. Richardson +21 more
TL;DR: The results suggest that optimization of dosing with this regimen could improve tolerability, potentially leading to improved patient outcomes.
Journal ArticleDOI
Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults
Amandine Le Bourgeois,Myriam Labopin,Thierry Guillaume,Jacques Delaunay,Yohann Foucher,Benoit Tessoulin,Florent Malard,Sameh Ayari,Pierre Peterlin,Sophie Derenne,Patricia Herry,Anne Cesbron,Katia Gagne,Laurence Lodé,Marina Illiaquer,Berthe-Marie Imbert-Marcille,Steven Le Gouill,Philippe Moreau,Mohamad Mohty,Patrice Chevallier +19 more
TL;DR: Human herpesvirus 6 reactivation during aplasia, lower unit-unit human leukocyte antigen matching, and younger UCB unit age, as new unfavorable predictive factors, may represent new parameters to take into account after double UCB allogeneic stem-cell transplantation in adults.